Celgene revenue was $15.28 b in FY, 2018 which is a (17.5%) year over year increase from the previous period.
Celgene revenue breakdown by business segment: 10.5% from Inflammation & Immunology, 89.4% from Hematology / Oncology and 0.1% from Other
Celgene revenue breakdown by geographic segment: 65.6% from U.S. and 34.4% from International
FY, 2017 | FY, 2018 | FY, 2016 | |
---|---|---|---|
Inflammation & Immunology | $1.28 b | $1.61 b | $1.02 b |
Other revenue | $30 m | $16 m | $44 m |
Hematology / Oncology | $11.69 b | $13.66 b | $10.17 b |
FY, 2017 | FY, 2018 | FY, 2016 | |
---|---|---|---|
U.S. | $8.32 b | $10.02 b | $7.01 b |
Europe | $3.33 b | $3.05 b | |
All other | $1.35 b | $1.17 b | |
International | $5.25 b |
Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.